NK Cell Therapy for Malignant Solid Brain Tumors

This is a multi-center, open-label investigator-initiated trial (IIT) designed to evaluate the safety, tolerability, and feasibility of combined intracranial and intravenous administration of ex vivo expanded and activated natural killer (NK) cells in adult patients with malignant solid brain tumors who have failed standard treatment modalities. The primary objective is to determine the maximum tolerated dose (MTD) or maximum feasible dose (MFD) of the combined NK cell therapy. Secondary objectives include preliminary assessment of anti-tumor activity as measured by progression-free survival (

Trial Details

NCT ID
NCT07552233
Phase
NA
Sponsor
Peking University Third Hospital
Status
RECRUITING
Cancer Type
Glioblastoma (GBM) Brain Cancer
Interventions
  • Autologous NK cells
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Qinhuangdao, Hebei, China|39.94104,119.58936
  • Zhengzhou, Henan, China|34.75778,113.64861
  • Zhengzhou, Henan, China|34.75778,113.64861

Key Eligibility Criteria

  • Male or female, age 18-70 years old (both ends included)
  • At least one evaluable lesion with previous biopsy or pathohistologic confirmation of malignant central nervous system tumor, with imaging suggesti…
  • Karnofsky Performance Status (KPS) ≥ 60%
  • Life expectancy \> 4 weeks, and must be able to undergo an MRI with contrast

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Glioblastoma (GBM) Brain Cancer Trials on Trialify →